All In Biotech

Drug Trial Radar · NCT06076304

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,720 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,720

Planned (sponsor's estimate)

Start

Nov 21, 2023

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Daniel MerensteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; Medstar Health Research Institute; University of Washington; Virginia Commonwealth University; University of California, Los Angeles; University of Wisconsin, Madison; Penn State College of Medicine
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sinus infections (also called acute rhinosinusitis or ARS) affect about 15% of adults each year, and are one of the top reasons people receive antibiotics in outpatient settings. Since most sinus infections are caused by viruses, many patients who take antibiotics for this condition do not actually benefit. Even though this has decreased over recent years, 70% of people are still prescribed them after a visit for ARS. Our goal is to better understand which patients truly benefit from antibiotics and which other treatment options can help people with sinus infections.

Conditions

  • Sinus Infection
  • Acute Sinusitis

Interventions

  • amoxicillin/clavulanate potassiumDrug

    Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days

  • PlaceboDrug

    Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days

  • Budesonide nasal sprayDrug

    Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptom ImprovementTime frame: Change from Day 1 to Day 3 in Phase 2; differences in longitudinal trends across groups during Phase 2

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • MedStar Health Research Institute

    Hyattsville, Maryland · Not yet recruiting

  • Penn State College of Medicine

    Hershey, Pennsylvania · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • University of Wisconsin-Madison

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.